LDOC1 (Gene)

Organism:

Homo sapiens

Synonyms:BCUR1, ENTREZ:23641, HGNC:6548, LDOC1 regulator of NFKB signaling, LDOC1, MIM:300402, Mar7, Mart7, NM_012317, NP_036449, RTL7, SIRH7

Omim:OMIM:300402

Id:ENSG00000182195

Hgnc:HGNC:6548

Entrez:23641

Ensembl:ENSG00000182195

Description:LDOC1 regulator of NFKB signaling

The protein encoded by this gene contains a leucine zipper-like motif and a proline-rich region that shares marked similarity with an SH3-binding domain. The protein localizes to the nucleus and is down-regulated in some cancer cell lines. It is thought to regulate the transcriptional response mediated by the nuclear factor kappa B (NF-kappaB). The gene has been proposed as a tumor suppressor gene whose protein product may have an important role in the development and/or progression of some cancers. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View LDOC1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with LDOC1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using LDOC1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for LDOC1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with LDOC1.

Results found

Linked to

	Label	Description
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 10 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE102467 3 V 2 PAZOPANIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876,GSE147877 2 V 7 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE165334 2 V 0 DABRAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 10 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE102467 3 V 2 PAZOPANIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE147876,GSE147877 2 V 7 ENZALUTAMIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE165334 2 V 0 DABRAFENIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.